Seoul, South Korea-based AI developer Neurophet has signed a memorandum of understanding with the Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) to offer its brain imaging AI devices across the network's participating medical institutions.
Under the agreement, ALZ-NET sites will receive discounted access to Neurophet Aqua, an MRI brain neurodegeneration imaging analysis tool; Neurophet Scale PET, a quantitative PET imaging analysis tool; and Neurophet Aqua AD Plus, an integrated brain imaging platform designed to support treatment decisions for Alzheimer's disease therapies, the company said. All three products have received clearance from the U.S. Food and Drug Administration (FDA).
The partnership will also focus on raising awareness of the importance of monitoring amyloid-related imaging abnormalities, Neurophet said.
Sponsored by the Alzheimer's Association and managed by the American College of Radiology, ALZ-NET collects and analyzes clinical and imaging data from patients receiving FDA-approved Alzheimer's therapies at voluntarily participating institutions.
